COMMENTS TO THE PAPER S. NODARI ET AL. «EFFECTS OF N-3 POLYUNSATURATED FATTY ACIDS ON LEFT VENTRICULAR FUNCTION AND FUNCTIONAL CAPACITY IN PATIENTS WITH DILATED CARDIOMYOPATHY»

1. Schultheiss H.P., Kühl U. Overview on Chronic Viral Cardiomyopathy/Chronic Myocarditis. Ernst Schering Res Found Workshop 2006;(55):3-18.

2. Køber L., Torp-Pedersen C., Carlsen J.E. et al. A trial of the angiotensin-converting-enzyme in patients with heart failure. N Engl J Med 1995; 333(25): 1670-1677.

3. Lechat P., Packer M., Chalon S. et al. Beta-blockers in heart failure: meta-analysis of randomized trials. Circulation 1998; 98(12): 1184-1191.

4. Louis A., Cleland J.G., Crabbe S. et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3(3):381-7.

5. GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223— 1130.

6. Nodari S., Triggiani M., Campia U. et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57(7): 870-9.

7. Wilson Tang W.H., Samara M.A. Polyunsaturated Fatty Acids in Heart Failure: Should We Give More and Giv Earlier? J Am Coll Cardiol 2011;57;880-883.